Drug Database
EP

epinephrine (Emerade)

✓ Approved

Bausch + Lomb Corporation · Small Molecule · Small Molecule

What is epinephrine?

epinephrine is a small molecule developed by Bausch + Lomb Corporation. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesEmerade
CompanyBausch + Lomb Corporation
Drug ClassSmall Molecule
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Bausch + Lomb Corporation

Therapeutic Indications

epinephrine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersAnaphylactic reaction✓ Approved

Related Research Articles

PubMedFrontiers in allergy2026-07-17

Bridging innovation and risk: the missing role of validated risk-stratification in IgE-mediated food allergy management.

Opseth Heather M HM, Gruver Michelle M

Over the last decade, the prevalence of IgE-mediated food allergies has increased, alongside therapeutic innovations such as oral immunotherapy (OIT), omalizumab, combination approaches, intranasal epinephrine, and emerging biomarker-guided strategies. This mini review synthesizes evidence published between 2019 and 2025 and evaluates how these advances intersect with persistent safety and clinical decision-making challenges. Although these therapies demonstrate promising efficacy, validated risk-stratification tools capable of guiding individual treatment selection are lacking. The proposed conceptual framework illustrates how patient characteristics, biomarkers, and treatment-specific risks may ultimately support individualized therapeutic decision-making.

PMID 42466328
Read full article →
PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-07-17

Photocatalytic/Bio-Catalytic Coupled Photoreactor for Asymmetric Reduction of Acetophenones Under Solar Light.

Shambhavee, Yadav Rajesh K RK, Singh Pooja P, Mishra Shaifali S et al.

Chiral alcohols are significant organic compounds that serve as key building blocks for the synthesis of many pharmaceuticals and fine chemicals. The asymmetric reduction of prochiral ketones via coupled photocatalytic-biocatalytic systems has emerged as one of the most promising and sustainable routes. In this study, we report an aminomethyl-polystyrene resin coupled eosin-B (PSR@Eb) solar light harvesting photocatalyst which is synthesized via acid-amine coupling approach. Notably,  the as prepared PSR@Eb photocatalyst exhibit an excellent photocatalytic activity for the NADPH regeneration and asymmetric reduction of acetophenones to a chiral alcohol (1-phenyl ethanol). Additionally, this asymmetric reduction proceeds under mild and environmentally benign conditions through alcohol dehydrogenase (ADH)-mediated catalysis, eliminating the need for stoichiometric metal-based reductants. This coupled photocatalytic-biocatalytic photoreactors offers a sustainable route for the synthesis of optically enriched alcohols, which are of significant application to the pharmaceutical, flavor and fragrance, and agrochemical industries.

PMID 42466997
Read full article →
PubMedCytotherapy2026-07-17

Quality control of biological raw materials to ensure the viral safety of cell and gene therapy products.

Nozaki Yusuke Y, Naito Satomi S, Ishii Ayana A, Tezuka Kyo K et al.

Most cell and gene therapy (CGT) products use human- or animal-derived raw materials during manufacturing. The viral safety of the final products must be ensured from the point of use of the biological raw materials. Cell therapy products, which involve living cells as the final product, are vulnerable to heat and chemicals and cannot be filtered. Therefore, it is not possible to establish a process for removing and inactivating viruses and microorganisms from these products, as is performed for biopharmaceuticals. Ensuring the viral safety of the final product requires rigorous control of the contamination risks posed by biological raw materials, which are considered more critical than those encountered in conventional biopharmaceutical manufacturing. Based on the consultation and review of CGT products by the Pharmaceuticals and Medical Devices Agency, we evaluated frequent issues and described the points to be considered regarding the quality control of biological raw materials used in the manufacturing of CGT products.

PMID 42462592
Read full article →
PubMedJournal of medical virology2026-07-17

Cepharanthine Inhibits Influenza A Virus Infection by Blocking Viral Attachment to Host Cells.

Chen Shan S, Pan Wenliang W, Ren Shuning S, Hou Xiaolin X

Influenza A virus (IAV) is characterized by high transmissibility and pathogenicity, posing a substantial threat to global public health. The rapid mutation of the IAV RNA genome undermines the efficacy of vaccines and prevention strategies, while the emergence of drug-resistant strains has further complicated control efforts-underscoring an urgent need for novel, effective anti-influenza therapeutics. Herein, we demonstrate that cepharanthine (CEP), a secondary metabolite isolated from Stephania spp., potently inhibits infection and replication of multiple IAV subtypes in vitro with its antiviral mechanism being independent of host innate immune response modulation. CEP treatment conferred significant protection to mice infected with a high dose of PR8. Further investigations revealed that CEP treatment during pre-infection and viral adsorption phases significantly suppresses IAV replication, markedly attenuates IAV-induced cytopathic effects, and enhances cell viability. Importantly, we identified for the first time that CEP strongly blocks IAV attachment to host cell membranes. Moreover, CEP administration significantly reduces disease severity in IAV-infected mice. These findings indicate that CEP exhibits broad-spectrum anti-IAV activity, providing a critical foundation for the development of novel anti-influenza pharmaceuticals.

PMID 42464733
Read full article →
PubMedJournal of the American Chemical Society2026-07-17

Controlled Precursor Differentiation Enables Palladium-Catalyzed Divergent Carbonylation of Cyclobutenols.

Liu Yu-Kun YK, Yang Peng P, Yang Hefei H, Zhang Jiajun J et al.

Controlling reaction selectivity is a central challenge in synthetic chemistry, particularly when multiple competing reactivity modes coexist within a single substrate. Existing strategies generally rely either on selectivity control during substrate activation or on downstream divergence from a common intermediate. However, these paradigms are less effective when distinct precursor states can independently evolve into distinct reaction manifolds. Herein, we introduce precursor differentiation as a distinct strategy for achieving divergent carbonylation. Through condition-controlled modulation of substrate evolution, a common cyclobutenol substrate can be selectively diverted into two distinct reactive precursors prior to catalytic engagement, thereby enabling access to two different carbonylation pathways. Under palladium catalysis, this strategy enables the highly selective synthesis of either hydroxyl-retained cyclobutanecarboxamides or cyclobutenamides from the same cyclobutenol platform. The method exhibits broad substrate scope (99 examples), consistently high selectivity (>20:1), and compatibility with pharmaceuticals and biologically relevant molecules. Furthermore, the resulting cyclobutenamide products serve as versatile platform intermediates for the selective synthesis of structurally distinct 3-azabicyclo[3.2.0]heptane and 3-azabicyclo[3.1.1]heptane frameworks. Mechanistic studies support a condition-controlled precursor differentiation process prior to carbonylation, providing a conceptual basis for achieving divergent carbonylation through selective control of precursor evolution.

PMID 42466643
Read full article →
PubMedJournal of separation science2026-07-17

Recent Advances in the Use of Natural Deep Eutectic Solvents for Natural Product Sample Preparation: Focus on Purification, Characterization, and Sustainability.

Cedeño-Fierro Valeria V, Grisales-Mejía Juan Felipe JF, Castañeda Harlen Gerardo Torres HGT, Mendiola Jose A JA

This review examines recent advances in the use of natural deep eutectic solvents (NaDES) for natural product sample preparation, with emphasis on extraction, purification, analytical compatibility, and sustainability. NaDES emerge as versatile, tunable, and biocompatible media that enhance the recovery and stability of diverse phytochemicals through extensive hydrogen‑bond networks and customizable polarity. The review summarizes current knowledge on NaDES formation principles, key physicochemical properties, and classification and evaluates their performance across conventional and advanced extraction techniques, including ultrasound, microwave, and pressure‑assisted processes. Evidence shows that NaDES frequently outperform traditional organic solvents in selectivity, extraction efficiency, and compound preservation. Their integration into purification workflows, chromatographic and spectroscopic analysis, and sensor platforms highlights growing analytical relevance. Sector‑specific applications in food, cosmetics, and pharmaceuticals illustrate the potential for direct formulation, improved bioactivity, and enhanced functional properties. Sustainability assessments using green metrics demonstrate that NaDES‑based methods reduce solvent consumption, waste generation, and environmental impact. Remaining challenges include viscosity management, removal strategies, and regulatory acceptance. Overall, NaDES represent a transformative class of green solvents that advances natural product research by combining efficiency, analytical compatibility, and strong alignment with green chemistry principles.

PMID 42466801
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about epinephrine